

Supplementary Table S1. Comparison of the patients with and without small bowel ulcer (>0.5 cm)

| | | Total <i>n</i>=40 | Presence of small- bowel ulcer, ≥0.5 cm <i>n</i>=11 | Absence of small- bowel ulcer, ≥0.5 cm <i>n</i>=29 | <i>p</i>-value |
|-------------------------------|--------------------------|------------------------------|--|---|-----------------------|
| SBCE score | Lewis score | 0 (0–192) | 339 (135–3503) | 0 (0–0) | <0.0001 |
| | CECDAI | 3 (0–6) | 8 (3–12) | 3 (0–6) | 0.0012 |
| | CDACE | 211 (0–420] | 730 (310–940) | 210 (0–370) | 0.0003 |
| Biomarkers/clinical activity: | | | | | |
| | Hb, g/dL | 13.7 (12.2–14.7) | 13.9 (12.3–14.6) | 13.7 (12.2–14.8) | 0.9396 |
| | Plt ×10 ⁴ /μL | 24.6 (21.1–29.2) | 24.9 (23.6–26.5) | 23.5 (20.7–29.7) | 0.4579 |
| | Alb, g/dL | 4.4 (4.2–4.7) | 4.3 (4–4.7) | 4.5 (4.2–4.7) | 0.1737 |
| | CRP, mg/dL | 0.08 (0.05–0.15) | 0.09 (0.06–0.18) | 0.08 (0.05–0.13) | 0.3018 |
| | LRG, μg/mL | 12.3 (8.9–14.1) | 14.1 (12.1–16.5) | 11.7 (9.3–13.5) | 0.0105 |
| | CDAI | 67 (29.5–89.8) | 85 (29–106) | 66 (30–85) | 0.1680 |

The data are median (interquartile range). Alb: albumin, CDAI: Crohn's Disease Activity Index, CDACE: Crohn's Disease Activity in Capsule Endoscopy, CECDAI: Capsule Endoscopy Crohn's Disease Activity Index, CRP: C-reactive protein, Hb: hemoglobin, Ht: hematocrit, IQR; inter quartile range, SBCE: small-bowel capsule endoscopy.

Supplementary Table S2. Comparison of the patients with and without Lewis score ≥ 350

| | | Total <i>n</i>=40 | Presence of Lewis score ≥ 350 <i>n</i>=5 | Absence of Lewis score < 350 <i>n</i>=35 | <i>p</i>-value |
|-------------------------------|-------------|------------------------------|---|---|-----------------------|
| | Lewis score | 0 (0–192) | 3503 (1589–3585) | 0 (0–135) | <0.0001 |
| SBCE score | CECDAI | 3 (0–6) | 12 (6.5–15.5) | 3 (0–6) | 0.0028 |
| | CDACE | 211 (0–420) | 831 (312–1042) | 210 (0–420) | 0.0106 |
| SB Ulcer ≥ 0.5 cm (%) | | 11 (27.5) | 5 (100) | 1 (17.1) | 0.0007 |
| Biomarkers/clinical activity: | | | | | |
| Hb, g/dL | | 13.7 (12.2–14.7) | 13.1 (11.7–14.4) | 13.7 (12.2–14.7) | 0.5394 |
| Plt $\times 10^4/\mu\text{L}$ | | 24.6 (21.1–29.2) | 24.7 (20.7–32) | 24.5 (21.1–28.5) | 0.5531 |
| Alb, g/dL | | 4.4 (4.2–4.7) | 4.2 (3.9–4.3) | 4.5 (4.2–4.7) | 0.0318 |
| CRP, mg/dL | | 0.08 (0.05–0.15) | 0.09 (0.07–0.26) | 0.08 (0.05–0.15) | 0.3892 |
| LRG, $\mu\text{g/mL}$ | | 12.3 (8.9–14.1) | 15.3 (14.4–17.3) | 11.7 (9.7–13.6) | 0.0030 |
| CDAI | | 67 (29.5–89.8) | 106 (88–125) | 65 (28–85) | 0.0069 |

The data are median (interquartile range). Abbreviations are explained in the footnote of Supplementary Table S1.

Supplementary Table S3. Comparison with LRG ≥ 16 $\mu\text{g/ml}$ as the cutoff

| | | Total <i>n</i>=40 | LRG ≥ 16 $\mu\text{g/ml}$ <i>n</i>=5 | LRG < 16 $\mu\text{g/ml}$ <i>n</i>=35 | <i>p</i>-value |
|---|-------------------------------|------------------------------|--|---|-----------------------|
| | Lewis score | 0 (0–192) | 196 (90–2092.5) | 0 (0–135) | 0.0270 |
| SBCE score | CECDAI | 3 (0–6) | 12 (5–15) | 3 (0–6) | 0.0090 |
| | CDACE | 211 (0–420) | 730 (371–1042) | 210 (0–420) | 0.0044 |
| Presence of small bowel ulcer ≥ 0.5 cm (%) | | 11 (27.5) | 3 (60) | 8 (22.9) | 0.1171 |
| Lewis score ≥ 350 (%) | | 5 (12.5) | 2 (40) | 3 (8.6) | 0.1088 |
| Biomarkers/clinical activity: | | | | | |
| | Hb, g/dL | 13.7 (12.2–14.7) | 14.5 (12.8–14.8) | 13.7 (12.1–14.7) | 0.4867 |
| | Plt $\times 10^4/\mu\text{L}$ | 24.6 (21.1–29.2) | 28 (24.4–30.8) | 23.6 (20.7–29.4) | 0.1706 |
| | Alb, g/dL | 4.4 (4.2–4.7) | 4.3 (3.9–4.5) | 4.4 (4.2–4.7) | 0.1732 |
| | CRP, mg/dL | 0.08 (0.05–0.15) | 0.21 (0.07–0.38) | 0.08 (0.05–0.14) | 0.0927 |
| | LRG, $\mu\text{g/mL}$ | 12.3 (8.9–14.1) | 16.8 (16.5–17.6) | 11.7 (9.7–13.6) | 0.0004 |
| | CDAI | 67 (29.5–89.8) | 85 (81–104) | 65 (28–89) | 0.0599 |

The data are median (interquartile range). Abbreviations are explained in the footnote of Supplementary Table S1.

Supplementary Table S4. Comparison by use of biologics

| | | Total <i>n</i>=40 | Biologics (-) <i>n</i>=15 | Biologics (+) <i>n</i>=25 | <i>p</i>-value |
|---|-------------------------------|------------------------------|--------------------------------------|--------------------------------------|-----------------------|
| | Lewis score | 0 (0–192) | 0 (0 – 225) | 0 [0 - 135] | 0.6071 |
| SBCE score | CECDAI | 3 (0–6) | 6 (3 – 10) | 3 [0 – 4] | 0.0224 |
| | CDACE | 211 (0–420) | 420 (210 – 730) | 210 [0 - 311] | 0.0357 |
| Presence of small bowel ulcer ≥ 0.5 cm (%) | | 11 (27.5) | 4 (26.7) | 7 (28) | 1.0000 |
| Lewis score ≥ 350 (%) | | 5 (12.5) | 2 (13.3) | 3 (12) | 1.0000 |
| Biomarkers/clinical activity: | | | | | |
| | Hb, g/dL | 13.7 (12.2–14.7) | 13.8 (12.1 – 14.7) | 13.7 [12.3 – 14.7] | 1.0000 |
| | Plt $\times 10^4/\mu\text{L}$ | 24.6 (21.1–29.2) | 25 (22.3 – 30.5) | 23.6 [20.9 – 28.1] | 0.2697 |
| | Alb, g/dL | 4.4 (4.2–4.7) | 4.4 (4.2 – 4.7) | 4.3 [4.2 – 4.8] | 0.9775 |
| | CRP, mg/dL | 0.08 (0.05–0.15) | 0.1 (0.07 – 0.21) | 0.08 [0.05 – 0.14] | 0.1572 |
| | LRG, $\mu\text{g/mL}$ | 12.3 (8.9–14.1) | 13.9 (11.7 – 14.4) | 10.8 [9.5 – 13.3] | 0.0314 |
| | CDAI | 67 (29.5–89.8) | 83 (28 – 106) | 66 [30 – 86] | 0.2883 |

Biologics (TNF inhibitor: *n*=20, Ustekinumab: *n*=4, Vedolizumab: *n*=1)

The data are median (interquartile range). Abbreviations are explained in the footnote of Supplementary Table S1.